OMEGA FUND MANAGEMENT LLC
Q2 2025 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001637359
· CRD 157753
· SEC-registered investment adviser
$154.4M Reported Value Total
OMEGA FUND MANAGEMENT, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $1,799,390,730, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $927.5M gross asset value
Venture Capital Fund: $806.5M · Private Equity Fund: $121.1M
Source: Form ADV filed 2026-03-26
Reported value
$154.4M
Quarter over quarter
-5.1%
Holdings
13
Top-10 concentration
97.8%
Key People
Form ADV owners & control persons
Otello (nmn) Stampacchia
MEMBER AND MANAGER
Francesco Luigi Draetta
MANAGER & MEMBER
Claudio Pier Antonio Nessi
MANAGER & MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2025 13F record
Q2 2025 13F filing summary
| Period of report | June 30, 2025 |
|---|---|
| Filed | August 14, 2025 |
| Form | 13F-HR |
| Reported value | $154.4M |
| Positions | 13 |
| Change in reported value | -8.9% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 97.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
10 | $185.7M |
|
Q1 2026 13F
Filed May 15, 2026
|
10 | $163.1M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
11 | $286.5M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
12 | $222.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
13 | $154.4M |
|
Q1 2025 13F
Filed May 15, 2025
|
13 | $169.5M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
12 | $154.2M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
11 | $160.0M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
11 | $135.0M |
|
Q1 2024 13F
Filed May 14, 2024
|
11 | $155.0M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
14 | $123.4M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
12 | $108.9M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
12 | $178.5M |
|
Q1 2023 13F
Filed May 15, 2023
|
14 | $153.3M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
16 | $296.7M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
19 | $273.1M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
21 | $313.3M |
|
Q1 2022 13F
Filed May 13, 2022
|
22 | $488.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
22 | $707.3M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
26 | $891.4M |
27 earlier quarters on file — choose one from the quarter menu above.
Top 13 holdings · Q2 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BBNX Beta Bionics Inc. | $28.9M | 18.75% |
| 2 | KMTS Kestra Med Technologies Ltd. | $27.3M | 17.67% |
| 3 | UPB Upstream Bio Inc. | $22.4M | 14.48% |
| 4 | NUVB Nuvation Bio | $21.5M | 13.94% |
| 5 | BCAX Bicara Therapeutics Inc. | $20.5M | 13.26% |
| 6 | REPL Replimune Group | $18.3M | 11.88% |
| 7 | LXEO Lexeo Therapeutics | $4.8M | 3.08% |
| 8 | IKNA Ikena Oncology | $3.0M | 1.95% |
| 9 | SANA Sana Biotechnology, Inc. | $2.3M | 1.49% |
| 10 | ALMS Alumis Inc. | $2.0M | 1.27% |
| 11 | ENGN enGene Holdings Inc. | $1.9M | 1.24% |
| 12 | IMUX Immunic Inc. | $1.2M | 0.81% |
| 13 | ENGNW enGene Holdings Inc. | $273.0K | 0.18% |
Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.